Matthijs C F Cysouw
Overview
Explore the profile of Matthijs C F Cysouw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puik J, Poels T, Hooijer G, Cysouw M, Verheij J, Wilmink J, et al.
Cancer Imaging
. 2025 Jan;
25(1):2.
PMID: 39810252
Background: Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, and lack accuracy in detecting lymph node metastases. F-Prostate-Specific Membrane Antigen (PSMA) PET/CT is...
2.
Palard-Novello X, Henrar R, Oprea-Lager D, Cysouw M, Schober P, de Geus-Oei L, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
52(4):1472-1480.
PMID: 39743615
Purpose: The aim of this study was to validate simplified methods for quantifying [Ga]Ga-FAPI-46 uptake against full pharmacokinetic modeling. Methods: Ten patients with pancreatobiliary cancer underwent a 90-min dynamic PET/CT...
3.
Luining W, Boeve L, Hagens M, Meijer D, de Weijer T, Ettema R, et al.
Eur Urol Oncol
. 2024 May;
PMID: 38693019
Background: Various risk classification systems (RCSs) are used globally to stratify newly diagnosed patients with prostate cancer (PCa) into prognostic groups. Objective: To compare the predictive value of different prognostic...
4.
Luining W, Oprea-Lager D, Vis A, van Moorselaar R, Knol R, Wondergem M, et al.
PLoS One
. 2023 Nov;
18(11):e0293672.
PMID: 37943772
Introduction: Radiomics extracted from prostate-specific membrane antigen (PSMA)-PET modeled with machine learning (ML) may be used for prediction of disease risk. However, validation of previously proposed approaches is lacking. We...
5.
Ambrosini V, Vaz S, Ahmadi Bidakhvidi N, Chanchou M, Cysouw M, Serani F, et al.
Eur J Nucl Med Mol Imaging
. 2023 Sep;
51(1):3-11.
PMID: 37689611
No abstract available.
6.
Eertink J, Zwezerijnen G, Cysouw M, Wiegers S, Pfaehler E, Lugtenburg P, et al.
Eur J Nucl Med Mol Imaging
. 2022 Aug;
49(13):4642-4651.
PMID: 35925442
Purpose: Biomarkers that can accurately predict outcome in DLBCL patients are urgently needed. Radiomics features extracted from baseline [F]-FDG PET/CT scans have shown promising results. This study aims to investigate...
7.
Luining W, Cysouw M, Meijer D, Hendrikse N, Boellaard R, Vis A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267481
Targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value in prostate cancer (PCa) care. PSMA positron emission tomography/computed tomography (PET/CT) is increasingly used in initial staging...
8.
Oprea-Lager D, Cysouw M, Boellaard R, Deroose C, de Geus-Oei L, Lopci E, et al.
Front Oncol
. 2021 Dec;
11:772530.
PMID: 34869009
Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change...
9.
Bodar Y, Koene B, Jansen B, Cysouw M, Meijer D, Hendrikse N, et al.
J Nucl Med
. 2021 Jan;
62(9):1264-1269.
PMID: 33509971
In prostate cancer (PCa) patients, the tumor-to-blood ratio (TBR) has been validated as the preferred simplified method for lesional F-DCFPyL (a radiolabeled prostate-specific membrane antigen ligand) uptake quantification on PET....
10.
de Vries B, Golla S, Ebenau J, Verfaillie S, Timmers T, Heeman F, et al.
Eur J Nucl Med Mol Imaging
. 2020 Sep;
48(3):721-728.
PMID: 32875431
Purpose: Visual reading of F-florbetapir positron emission tomography (PET) scans is used in the diagnostic process of patients with cognitive disorders for assessment of amyloid-ß (Aß) depositions. However, this can...